Xconomy | National - Business + Technology in the Exponential Economy

Alkermes

http://alkermes.com

Alkermes focuses on therapies for widespread, chronic diseases, such as central nervous system disorders, addiction and diabetes, where we feel we have the opportunity to make the greatest impact.

Is this your company? Click here to submit updated profile information.

company data powered by

Alkermes - Key Facts and Statistics

Headquarters
88 Sidney Street
Cambridge,
Massachusetts 02139-4137
United States

Ownership: Public

Status: Alive

Related News From Xconomy

- Amylin & Takeda Halt Obesity Drug Development
- Aug 05 2011
- Bydureon Sent Back to FDA
- Jul 28 2011
- Rib-X Inks Sanofi Deal, Zafgen Gets $33M Series C, Allegro Adds $5.4M, & More Boston-Area Life Sciences News
- Jul 08 2011
- Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial Demanded by FDA
- Jul 07 2011
Prev | Next
news powered by

- Alkermes Wins Over Investors With Plan To Become Trans-Atlantic “Big Biotech”
- Jul 06 2011
- Amylin, Alkermes Diabetes Med OKd in EU
- Jun 21 2011
- Varian Bought by Applied Materials, Nuance Picks Up Equitrac, Alkermes Pays $960M for Elan Unit, & More Boston-Area Deals News
- May 11 2011
- Alkermes Acquires Elan Drug Manufacturing Unit for $960M
- May 09 2011
Prev | Next
news powered by

- West Wireless Repositions Itself as an Impartial Arbiter, Amylin Makes Headway in Europe, VCs Debate Viability of Venture-Backed Biotech, & More San Diego Life Sciences News
- Apr 21 2011
- The Bob Langer and Polaris Family Tree: From Acusphere to Momenta to Visterra
- Apr 19 2011
- Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug
- Apr 15 2011
- Editor’s Picks: Xconomy Boston’s Top 20 Stories of the First Quarter
- Mar 31 2011
Prev | Next
news powered by

- Genzyme-Spinout Peptimmune Files for Chapter 7 Liquidation
- Mar 23 2011
- Amylin and Takeda Suspend Obesity Study to Consider Metreleptin Data
- Mar 16 2011
- Amylin, Lilly, Alkermes Diabetes Drug Doesn’t Match Rival in Head-to-Head Study
- Mar 03 2011
- Alkermes Sees Chance to Reinvent Vivitrol For Fighting Drug Addiction, Not Just Alcoholism
- Feb 18 2011
Prev | Next
news powered by

- Rib-X Wrappes Up $20M, Oxford Closes $66M on Sixth Fund, Ocular Adds $6M, & More Boston-Area Deals News
- Jan 14 2011
- Alkermes Finds New Home For Inhaled Drug-Delivery Tech with Civitas Spinout
- Jan 10 2011
- Lilly Funds Cerulean, Genzyme Sells Diagnostics Unit, Roche Ends RNAi Program, & More Boston-Area Life Sciences News
- Nov 19 2010
- Alkermes CEO Leans on Internal Pipeline as Bydureon Hangs Out in the Penalty Box
- Nov 15 2010
Prev | Next
news powered by

- Alkermes Drug Approved for Opioid Addiction, Genzyme Faces Shareholder Lawsuits, NinePoint Gets $33M, & More Boston-Area Life Sciences News
- Oct 15 2010
- Amylin, Alkermes Eagerly Await FDA Verdict (Again) For Once-Weekly Diabetes Drug
- Oct 15 2010
- Alkermes Gets Drug Approval
- Oct 12 2010
- Alkermes Wins FDA Panel Nod
- Sep 16 2010
Prev | Next
news powered by

- $8M for Acceleron
- Jun 22 2010
- Of Angel Tsunamis, the X Prize, Wireless Power, Mobile Health, & More —XSITE 2010 is Tomorrow
- Jun 16 2010
- XSITE 2010: The Xconomy Summit on Innovation, Technology & Entrepreneurship
- Jun 08 2010
- Amylin, Alkermes Get New FDA Date
- May 06 2010
Prev | Next
news powered by

- Novartis Buys Alnylam Shares, Xconomy Holds First Ever Health IT Forum, Vertex Alumni Spread Throughout Life Sciences Sector, & More Boston-Area Life Sciences News
- Apr 30 2010
- Warner Bros. Acquires Turbine, Athenahealth Taps IBM, Alkermes Reveals Diabetes Drug Royalty, & More Boston-Area Deals News
- Apr 28 2010
- Alkermes Reveals Higher-Than-Expected Royalty on Diabetes Drug
- Apr 26 2010
- Alkermes Files Drug App With FDA
- Apr 13 2010
Prev | Next
news powered by

- Amylin, Alkermes Sit in Suspense For FDA Verdict on Once-Weekly Diabetes Drug
- Mar 10 2010
- FDA Diabetes Drug Review Slowed by Snow
- Feb 25 2010
- Alkermes Unveils Cheaper, Easier Technique for Making Drugs Last Longer in Blood
- Feb 04 2010
- Acceleron Pharma Reports $10.9M Financing
- Dec 16 2009
Prev | Next
news powered by

- A Graceful Exit for Gloucester, Pink Slips at Sermo, A Half a Billion Bucks for Vertex, & More Boston-Area Life Sciences News
- Dec 09 2009
- $443 million for Vertex, $25.5M for Forma, $8M for Contour Semiconductor, & More Boston-Area Deals News
- Dec 04 2009
- Alkermes Bets $10M on Long-Lasting Drug Technology from Startup Neighbor, Acceleron
- Dec 03 2009
- Alkermes to Seek FDA Approval of Anti-Addiction Drug
- Nov 16 2009
Prev | Next
news powered by

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.